clinical trial · NCT05818683
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC·phase1·recruiting·n = 300
Metastatic Castration-resistant Prostate NeoplasmsMetastatic Hormone-sensitive Prostate CancerPasritamigCetrelimabCabazitaxelDocetaxelApalutamideEnzalutamideDarolutamideAbiraterone acetate plus prednisone (AAP)
brief summary
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
started
Apr 26, 2023
primary completion
Aug 31, 2027
completion
May 23, 2028
last updated
Apr 13, 2026
official title
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol